DexCom (DXCM) PT Raised to $112 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil steadies on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Five things to watch in markets in the week ahead
- Citi sees room for further equities upside in 2027 on resilient earnings growth
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $85.36 --0%
Rating Summary:
32 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 24
Rating Summary:
32 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 24
Join SI Premium – FREE
BMO Capital raised its price target on DexCom (NASDAQ: DXCM) to $112.00 (from $86.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Integra LifeSciences (IART) PT Lowered to $15 at BMO Capital
- NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $42 at RBC Capital
- International Paper (IP) PT Lowered to $35 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
